Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein

Silence Therapeutics

20/06/2024 13:21

June 20 (Reuters) - Silence Therapeutics PLC  SLNCF.PK :
    * SILENCE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE 48-WEEK
DATA
FROM PHASE 2 STUDY OF ZERLASIRAN IN PATIENTS WITH ELEVATED
LIPOPROTEIN(A)
    * SILENCE THERAPEUTICS: STUDY DEMONSTRATED HIGHLY
SIGNIFICANT AND
SUSTAINED REDUCTIONS IN LP(A) TO WEEK 48

Source text for Eikon:  ID:nBwfCPg0a 
Further company coverage:  SLNCF.PK 

 ((Reuters.Briefs@thomsonreuters.com;))